[1] DEFRONZO R A. Banting Lecture. From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus[J]. Diabetes, 2009, 58(4):773-795. [2] TAHRANI A A, BAILEY C J, DEL PRATO S, et al. Management of type 2 diabetes:new and future developments in treatment[J]. Lancet, 2011, 378(9786):182-197. [3] BAILEY C J. Renal glucose reabsorption inhibitors to treat diabetes[J]. Trends Pharmacol Sci, 2011, 32(2):63-71. [4] 金磊, 王帅, 王欣, 等. 高脂诱导BRL-3A细胞胰岛素抵抗模型的建立[J]. 癌变·畸变·突变, 2016, 28(1):46-50, 55. [5] LINSEL-NITSCHKE P, G-TZ A, ERDMANN J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease:a Mendelian Randomisation study[J]. PLoS One, 2008, 3(8):e2986. [6] REED D M, STRONG J P, RESCH J, et al. Serum lipids and lipoproteins as predictors of atherosclerosis. An autopsy study[J]. Arteriosclerosis, 1989, 9(4):560-564. [7] KONG W J, WEI J, ABIDI P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J]. Nat Med, 2004, 10(12):1344-1351. [8] 石建辉, 苗明三, 田效志. 槐角颗粒冲剂降脂作用研究[J]. 河南中医, 1997, 17(6):347-348. [9] 袁崇均, 王笳, 陈帅, 等. 大孔树脂对槐角总黄酮分离纯化工艺研究[J]. 四川中医, 2008, 26(2):40-42. [10] GENTILE C L, FRYE M, PAGLIASSOTTI M J. Endoplasmic Reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease[J]. Antioxid Redox Signal, 2011, 15(2):505-521. [11] MALHI H, KAUFMAN R J. Endoplasmic Reticulum stress in liver disease[J]. J Hepatol, 2011, 54(4):795-809. [12] SAMUEL V T, PETERSEN K F, SHULMAN G I. Lipid-induced insulin resistance:unravelling the mechanism[J]. Lancet, 2010, 375(9733):2267-2277. [13] ROSEN E D, SPIEGELMAN B M. What we talk about when we talk about fat[J]. Cell, 2014, 156(1/2):20-44. [14] TILG H, MOSCHEN A R. Adipocytokines:mediators linking adipose tissue, inflammation and immunity[J]. Nat Rev Immunol, 2006, 6(10):772-783. |